三黄煎剂联合吡柔比星、多西他赛、环磷酰胺新辅助化疗治疗三阴乳腺癌临床研究  

Study of Sanhuang decoction combined with pirarubicin,docetaxel and cyclophosphamide for neoadjuvant chemotherapy in the treatment of triple negative breast cancer

作　　者：刘小娜[1] 郝娜 马晓霞[1] 周瑜辉[1] 汤小江[1] LIU Xiaona;HAO Na;MA Xiaoxia;ZHOU Yuhui;TANG Xiaojiang(Department of Breast Surgery,the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)

机构地区：[1]西安交通大学第一附属医院乳腺外科,陕西西安710061

出　　处：《陕西中医》2021年第10期1367-1370,共4页Shaanxi Journal of Traditional Chinese Medicine

基　　金：陕西省重点研发计划项目(2021SF-010)。

摘　　要：目的:探究三黄煎剂联合吡柔比星、多西他赛、环磷酰胺新辅助化疗治疗三阴乳腺癌的临床疗效。方法:选取三阴乳腺癌患者148例,随机分为对照组和研究组,每组74例。对照组给予吡柔比星、多西他赛、环磷酰胺新辅助化疗,研究组在对照组基础上联合三黄煎剂进行治疗,记录两组治疗后的临床疗效,随访2年的总生存期(OS)、无进展生存期(PFS)及Kamofsky评分,检测两组治疗前后免疫指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平,以及记录两组治疗期间不良反应的发生情况。结果:研究组治疗后的总缓解率、总控制率均比对照组高(P<0.05);治疗后,研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均比对照组的更高(P<0.05),CD8^(+)水平比对照组更低(P<0.05);两组OS、PFS比较差异无统计学意义(P>0.05),但研究组Kamofsky评分比对照组高(P<0.05);治疗期间,研究组的不良反应发生率比对照组低(P<0.05)。结论:三黄煎剂联合吡柔比星、多西他赛、环磷酰胺新辅助化疗治疗三阴乳腺癌能提高临床疗效,增强免疫力,改善预后,用药安全性更高。Objective:To explore the clinical efficacy of Sanhuang decoction combined with pirubicin,docetaxel,and cyclophosphamide for neoadjuvant chemotherapy in the treatment of triple-negative breast cancer(TNBC).Methods:A total of 148 TNBC patients were randomly divided into control group and study group,74 cases in each group.The control group was given pirarubicin,docetaxel and cyclophosphamide for neoadjuvant chemotherapy,while study group was treated with Sanhuang decoction on basis of control group.The clinical curative effect after treatment,overall survival(OS)of 2-year follow-up,progression-free survival(PFS)and Kamofsky scores in both groups were recorded.The levels of immune indexes(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))in both groups before and after treatment were detected.The occurrence of adverse reactions during treatment in both groups was recorded.Results:After treatment,total remission rate and total control rate were higher in study group than control group(P<0.05).After treatment,levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were higher in study group than control group(P<0.05),while CD8^(+)level was lower in study group(P<0.05).There was no significant difference in OS or PFS between the two groups(P>0.05).Kamofsky score was higher in study group than control group(P<0.05).During treatment,incidence of adverse reactions was lower in study group than control group(P<0.05).Conclusion:Sanhuang decoction combined with pirarubicin,docetaxel and cyclophosphamide for neoadjuvant chemotherapy in treatment of TNBC can improve clinical curative effect,enhance immunity,and improve prognosis,with higher medication safety.

关 键 词：三阴乳腺癌 三黄煎剂 吡柔比星 多西他赛 环磷酰胺 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]